BioCryst Pharmaceuticals, Inc.

BCRX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$12,899$5,085$32-$26,795
Dep. & Amort.$335$329$331$309
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$21,304$21,368$21,339
Change in WC-$1,370$2,377-$62,132-$11,331
Other Non-Cash$29,247$12,207$12,884$11,265
Operating Cash Flow$41,111$41,302-$27,517-$5,213
Investing Activities
PP&E Inv.-$1,344-$179-$143-$675
Net Acquisitions$0$0$0$0
Inv. Purchases-$58,634-$29,341-$48,762-$39,528
Inv. Sales/Matur.$73,000$58,647$76,000$58,000
Other Inv. Act.$550$0$0$0
Investing Cash Flow$13,572$29,127$27,095$17,797
Financing Activities
Debt Repay.-$60,341-$70,044-$516-$356
Stock Issued$2,668$9$6$5
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$628-$3,651$1,039-$3,670
Financing Cash Flow-$58,301-$73,686$529-$4,021
Forex Effect-$250-$13,699$451-$1,304
Net Chg. in Cash-$3,868-$16,956$558$7,259
Supplemental Information
Beg. Cash$88,525$106,881$106,323$99,064
End Cash$84,657$89,925$106,881$106,323
Free Cash Flow$39,767$41,123-$27,660-$5,888